Novo Nordisk - ADR

NVO

$106.01

+50.3% (1 year change)

Market Cap

$185 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$61.99 - $107.24

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

0.0x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$1.47 (1.41%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $185 Billion
Enterprise Value -
Dividend Yield $1.47 (1.41%)
1 Year Return +51.7%
52-Week High $107.24
52-Week Low $61.99
Beta 0.0
Outstanding Shares 1.77 Billion
Avg 30 Day Volume 862 Thousand

Valuation

P/E Ratio 0.0
PEG -
Earnings per Share $0.00
Price to Sales Ratio -
Price to Book Ratio -
Revenue to Enterprise Value -
EBIT to Enterprise Value -
Total Debt to Enterprise Value -
Debt to Equity -

Profitability

Revenue -
Gross Profit -
EBIT -
Net Income -
Profit Margin -
Quarterly Earnings Growth (YoY) -
Return on Equity -
Return on Assets -
Return on Invested Capital -

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q1 2021 Q2 2021 Q3 2021 Q4 2021

About Novo Nordisk - ADR

CEO: Lars Fruergaard Joergensen

Industry: Medicinal and Botanical Manufacturing

Similar stocks

Pfizer Inc.
Lilly(Eli) & Co
Sanofi - ADR

News

Novo Nordisk A/S (NYSE:NVO) Upgraded to Buy at SEB Equities

Novo Nordisk A/S (NYSE:NVO) Upgraded to Buy at SEB Equities

SEB Equities upgraded shares of Novo Nordisk A/S (NYSE:NVO) from a hold rating to a buy rating in a research report report published on Monday, The Fly reports. A number of other equities research ...

 Dakota Financial News Dakota Financial News, 3 days ago
Thinking the unthinkable

Thinking the unthinkable

Lets take a quick look at the insulin market. Even with the advent of biosimilars Lilly, Novo Nordisk and Sanofi still dominate the market. While insulin remains the most heavily rebated drug it at...

Diabetic Investor Diabetic Investor, 4 days ago
Novo Nordisk Awarded the Best Place to Work Certification in Iraq For 2021

Novo Nordisk Awarded the Best Place to Work Certification in Iraq For 2021

BAGHDAD--(BUSINESS WIRE)-- #BPTW4Iraq--Novo Nordisk Iraq, an affiliate of the global healthcare company with more than 90 years of innovation and leadership in diabetes care, has been officially re...

Business Wire Business Wire, 5 days ago